UBX

Unity Biotechnology, Inc. [UBX] Stock Forecast

Q: What is Unity Biotechnology, Inc. stock symbol ?

Unity Biotechnology, Inc. is a US stock, located in South san francisco of Ca and trading under the symbol UBX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

UBX Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

UBX has more than 22 years of cash runway (275 months)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 155.94%

Earnings are expected to fall -100% next year

In the News

04:45 27 Sep 2023 UBX

Unity (UNX) Down on Disappointing Results From Wet AMD Study

Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.

12:00 27 Sep 2023 UBX

Why Is Unity Biotechnology (UBX) Stock Down 52% Today?

Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development by the company that it's testing for use with patients suffering from wet age-related macular degeneration ( AMD ).

12:45 27 Sep 2023 UBX

Unity Biotechnology (UBX) Stock Pops on Positive Study Data

Unity Biotechnology (NASDAQ: UBX ) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325. UBX1325 is the company's treatment in development to treat patients dealing with diabetic macular edema (DME).

08:15 27 Sep 2023 UBX

Unity Biotechnology: Share Consolidation On The Back Of Positive Trial Results

A small cap biotech targeting diseases of ageing, with a lead compound focusing on ophthalmology that recently reported positive trial results. Not overly reliant on debt and has reported some revenues with relatively stable overall financials.

01:32 27 Sep 2023 UBX

All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy

UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

07:00 27 Sep 2023 UBX

The Three Best Anti-Aging Stocks to Buy in September

Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth companies.

08:00 27 Sep 2023 UBX

UNITY Biotechnology to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following investor conferences in September.

11:17 27 Sep 2023 UBX

Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now

UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

06:00 27 Sep 2023 UBX

Hot Penny Stocks to Add to Your Watchlist Right Now

Here's what you need to know about trading penny stocks on August 15th The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:05 27 Sep 2023 UBX

Why Is Unity Biotechnology (UBX) Stock Up 71% Today?

Source: everything possible / Shutterstock.com Unity Biotechnology (NASDAQ: UBX ) stock is surging higher on Friday following the release of its earnings report for the second quarter of 2022. That report starts with the company's current cash position sitting at $64.5 million.

UBX Financial details

Company Rating

Buy

Market Cap

36.07M

Income

-52.33M

Revenue

-236K

Book val./share

3.42

Cash/share

4.79

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

06 Nov 2023

P/E

-0.66

Forward P/E

PEG

0.11

P/S

-147.25

P/B

0.69

P/C

0.5

P/FCF

-0.8

Quick Ratio

3.19

Current Ratio

3.28

Debt / Equity

0.87

LT Debt / Equity

0.59

EPS (TTM)

-4.08

EPS next Y

EPS next Q

EPS this Y

-43.49%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

1.19%

SMA20

-33.33%

SMA50

-33.33%

SMA100

Inst Own

1.11%

Inst Trans

ROA

-52%

ROE

-83%

ROC

-0.63%

Gross Margin

100%

Oper. Margin

21043%

Profit Margin

22173%

Payout

Shs Outstand

14.6M

Shs Float

13.36M

Target Price

52W Range

1.461-5.72

52W High

-51.68%

52W Low

+141.59%

RSI

Rel Volume

0.4

Avg Volume

108.61K

Volume

43.48K

Perf Week

-3.36%

Perf Month

-5.26%

Perf Quarter

61.06%

Perf Half Y

23.89%

Beta

0.612033

Volatility

0.07%, 0.09%

Prev Close

1.51%

Price

2.4159

Change

0.24%

UBX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0.86	0.02
Net income per share	-27.02	-17.16	-18.06	-10.76	-6.08
Operating cash flow per share	-20.03	-16.6	-15.4	-8.07	-5.37
Free cash flow per share	-20.48	-16.96	-15.53	-8.11	-5.38
Cash per share	60.54	29.22	19.21	15.78	9.98
Book value per share	56.84	27.67	16.29	10.67	7.04
Tangible book value per share	56.84	27.67	16.29	10.67	7.04
Share holders equity per share	56.84	27.67	16.29	10.67	7.04
Interest debt per share	1.17	0	12.74	9.81	5.36
Market cap	459.67M	314.53M	266.53M	81.49M	26.01M
Enterprise value	444.39M	277.06M	307.7M	100.14M	60.64M
P/E ratio	-6.02	-4.2	-2.9	-1.36	-0.45
Price to sales ratio	0	0	0	17.03	110.23
POCF ratio	-8.12	-4.34	-3.4	-1.81	-0.51
PFCF ratio	-7.94	-4.25	-3.37	-1.8	-0.51
P/B Ratio	2.86	2.61	3.22	1.37	0.39
PTB ratio	2.86	2.61	3.22	1.37	0.39
EV to sales	0	0	0	20.93	256.94
Enterprise value over EBITDA	-6.31	-3	-3.42	-1.74	-1.08
EV to operating cash flow	-7.85	-3.83	-3.93	-2.22	-1.19
EV to free cash flow	-7.68	-3.74	-3.9	-2.21	-1.19
Earnings yield	-0.17	-0.24	-0.34	-0.74	-2.22
Free cash flow yield	-0.13	-0.24	-0.3	-0.56	-1.97
Debt to equity	0	0	0.77	0.87	0.71
Debt to assets	0	0	0.41	0.41	0.38
Net debt to EBITDA	0.22	0.41	-0.46	-0.32	-0.61
Current ratio	10.43	7.52	6.97	5.45	4.92
Interest coverage	-23.99	0	-72.7	-17.84	-16.18
Income quality	0.74	0.88	0.83	0.74	0.85
Dividend Yield	0.13	0	0	0	0
Payout ratio	-0.8	0	0	0	0
Sales general and administrative to revenue	0	0	0	4.82	88.77
Research and developement to revenue	0	0	0	8.03	156.18
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.02	0.02	0.01	0	0
Capex to revenue	0	0	0	-0.04	-0.41
Capex to depreciation	-0.58	-0.6	-0.19	-0.07	-0.04
Stock based compensation to revenue	0	0	0	2.41	39.74
Graham number	185.91	103.37	81.37	50.82	31.04
ROIC	-0.51	-0.68	-0.51	-0.4	-0.39
Return on tangible assets	-0.42	-0.5	-0.59	-0.48	-0.46
Graham Net	53.22	22.23	4.77	4.11	3.93
Working capital	156.38M	112.27M	86.4M	73.89M	76.92M
Tangible asset value	160.69M	120.71M	82.88M	59.57M	66.85M
Net current asset value	152.28M	98.97M	27.43M	25.36M	39.03M
Invested capital	0	0	0.77	0.87	0.71
Average receivables	691K	0	0	0	0
Average payables	3.61M	5.02M	3.87M	2.27M	1.89M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.48	-0.62	-1.11	-1.01	-0.86
Capex per share	-0.45	-0.36	-0.13	-0.03	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	0.03	0	-0.02	0	0
Net income per share	-2.02	-1.42	-0.97	-0.84	-0.85
Operating cash flow per share	-2.14	-1.08	-0.73	-0.79	-0.77
Free cash flow per share	-2.16	-1.08	-0.74	-0.79	-0.77
Cash per share	9.32	9.82	6.7	5.83	4.79
Book value per share	5.77	7.8	4.73	4.1	3.42
Tangible book value per share	5.77	7.8	4.73	4.1	3.42
Share holders equity per share	5.77	7.8	4.73	4.1	3.42
Interest debt per share	7.11	4.83	3.42	3.34	3.05
Market cap	39.06M	39.78M	38.75M	23.33M	36.79M
Enterprise value	67.94M	65.04M	73.37M	47.19M	60.75M
P/E ratio	-0.7	-0.7	-0.7	-0.48	-0.75
Price to sales ratio	165.49	0	-164.17	0	0
POCF ratio	-2.63	-3.66	-3.74	-2.06	-3.32
PFCF ratio	-2.61	-3.65	-3.72	-2.06	-3.32
P/B Ratio	0.98	0.51	0.58	0.4	0.74
PTB ratio	0.98	0.51	0.58	0.4	0.74
EV to sales	287.9	0	-310.88	0	0
Enterprise value over EBITDA	-5.84	-5.28	-5.57	-4.78	-5.57
EV to operating cash flow	-4.58	-5.99	-7.08	-4.17	-5.48
EV to free cash flow	-4.53	-5.96	-7.05	-4.17	-5.48
Earnings yield	-0.36	-0.36	-0.36	-0.52	-0.33
Free cash flow yield	-0.38	-0.27	-0.27	-0.49	-0.3
Debt to equity	1.21	0.61	0.71	0.8	0.87
Debt to assets	0.5	0.35	0.38	0.41	0.43
Net debt to EBITDA	-2.48	-2.05	-2.63	-2.42	-2.2
Current ratio	4.13	6.12	4.92	4	3.28
Interest coverage	-13.71	-15.16	-14.06	-10.63	-12.22
Income quality	1.13	0.79	0.73	1.04	0.91
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	20.94	0	-22.37	0	0
Research and developement to revenue	32	0	-36.59	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0	0	0	0
Capex to revenue	-0.64	0	0.16	0	0
Capex to depreciation	-0.25	-0.09	-0.09	0	0
Stock based compensation to revenue	9.53	0	-9.57	0	0
Graham number	16.21	15.78	10.17	8.82	8.07
ROIC	-0.11	-0.09	-0.1	-0.09	-0.11
Return on tangible assets	-0.14	-0.1	-0.11	-0.11	-0.12
Graham Net	0.99	4.08	2.64	1.94	1.36
Working capital	51.4M	85.95M	76.92M	64.8M	50.74M
Tangible asset value	39.93M	78.57M	66.85M	58.63M	49.41M
Net current asset value	10.16M	44.9M	39.03M	30.75M	21.37M
Invested capital	1.21	0.61	0.71	0.8	0.87
Average receivables	0	0	0	0	871.5K
Average payables	2.38M	1.94M	2.12M	1.63M	1.46M
Average inventory	0	0	0	0	880.5K
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.35	-0.18	-0.21	-0.21	-0.25
Capex per share	-0.02	0	0	0	0

UBX Frequently Asked Questions

What is Unity Biotechnology, Inc. stock symbol ?

Unity Biotechnology, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol UBX

What is Unity Biotechnology, Inc. stock quote today ?

Unity Biotechnology, Inc. stock price is $2.4159 today.

Is Unity Biotechnology, Inc. stock public?

Yes, Unity Biotechnology, Inc. is a publicly traded company.

Something similar

Top by Market Cap

RILYO

CANE

FB2A.DE

Company Profile

Volume Average 108.61K
Market Capitalization 36.07M
Employee 22
CEO Dr. Anirvan Ghosh Ph.D.
Headquarters South San Francisco,CA,US
IPO Date 2018-05-03
Website https://unitybiotechnology.com

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.